|
|
Background: TTC39A (tetratricopeptide repeat domain protein 39A) belongs to the structural family of tetratrico-peptide domain proteins. TTC39A had not been researched in cancers. The purpose of this study was to reveal the potential role of TTC39A in cancers.
Methods: In total, 33 cancers were included in this study. All the data came from the Cancer Genome Atlas (TCGA) database. The expression of TTC39A was explored in the 33 cancers. The relationship between the expression of TTC39A and prognosis, clinical characteristics, and immune infiltration was also explored. Paraffin-embedded cancer tissue microarrays (TMA) were used to detect the expression of TTC39A in LIHC (liver hepatocellular carcinoma) and LGG (brain lower grade glioma).
Results: The expression of TTC39A was higher in many cancers, compared with the corresponding normal tissues. For patients with LGG, LIHC, and SKCM (skin cutaneous melanoma), higher expression of TTC39A indicated worse OS. Survival analysis in clinical samples indicated that high expression of TTC39A was associated with shorter overall survival. The expression of TTC39A was related to the immune infiltration of some immune cells in LGG, LIHC, and SKCM. Also, the expression of TTC39A combined with the immune infiltration level of some immune cells could affect the OS of patients with these three cancers. Functional enrichment analysis and gene set enrichment analysis (GSEA) showed that TTC39A might play a role in many biological processes.
Conclusions: The expression of TTC39A was significantly higher in many cancers. TTC39A was associated with the prognosis of patients with LGG, LIHC, and SKCM, whether they were combined with the immune infiltration level of some immune cells or not. In these three cancers, TTC39A might play a role in some important biological processes.
DOI: 10.7754/Clin.Lab.2024.240923
|
